Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
| ▸ | RET | P07949 | 8/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30124483 | 0.85 | PRMT5 (0.41) | PRMT5WDR77USP30RETAAK1 | |
| SCHEMBL29182750 | 0.80 | RET (0.39) | RETCYP11B2RORCPIK3CDPIK3R1 | |
| SCHEMBL22499844 | 0.80 | CYP11B2 (0.42) | RETCYP11B2RORC | |
| SCHEMBL30931113 | 0.80 | RET (0.39) | RETCYP11B2RORCPIK3CDPIK3R1 | |
| SCHEMBL29689562 | 0.80 | CYP11B2 (0.42) | RETCYP11B2RORC | |
| SCHEMBL29182747 | 0.80 | RET (0.39) | RETCYP11B2RORCPIK3CDPIK3R1 | |
| SCHEMBL9904509 | 0.80 | USP30 (0.47) | PRMT5WDR77USP30 | |
| SCHEMBL20069993 | 0.79 | USP30 (0.44) | PRMT5WDR77USP30RETAAK1 | |
| SCHEMBL902176 | 0.78 | GPR119 (0.47) | USP30PIK3CA | |
| SCHEMBL30124814 | 0.78 | RET (0.37) | RETCYP11B2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179059-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| US-12162870-B2 | Anticancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| EP-4351560-A1 | ANTICANCER COMPOUNDS | The Regents of the University of California (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-01-26 | — | — | US | disclosed |
| WO-2022261204-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179059-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | PRMT5 2050/4885WDR77 979/4885USP30 3526/4885 |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | PRMT5 2050/4885WDR77 979/4885USP30 3526/4885 |
| US-12162870-B2 | Anticancer compounds | BET1, BRD4, BICRA | PRMT5 2050/4885WDR77 979/4885USP30 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.